US Edition
Published • loading... • Updated
FDA takes aim at Hims and other telehealth services in drug advertising blitz
The FDA targets telehealth firms for promoting unapproved compounded weight loss drugs with misleading claims, issuing over 100 cease and desist letters to protect consumer safety.
- On September 9, the FDA issued warning letters to Hims & Hers and other telehealth companies for false claims about their compounded weight-loss drugs.
- The crackdown follows a Trump administration memo directing the FDA and Health Secretary Kennedy to ensure pharmaceutical ads are truthful and non-misleading.
- The FDA reprimanded Hims for suggesting that its compounded treatments include the identical medication components found in approved drugs like Wegovy, despite the agency only allowing such compounding during shortages—which have recently been lifted.
- The letters included cease and desist language and more than 100 letters were sent, marking the FDA’s first direct enforcement against online platforms like Hims, whose shares fell over 6% on Tuesday.
- This enforcement signals increased FDA scrutiny on telehealth drug advertising and may curb misleading promotion of compounded medications despite companies' claims of added benefits.
Insights by Ground AI
32 Articles
32 Articles
Associated Press News+30 Reposted by 30 other sources
FDA takes aim at Hims and other telehealth services in drug advertising blitz
The Trump administration has issued its first warnings to online services that offer unofficial versions of popular drugs like the blockbuster obesity treatment Wegovy.
·United States
Read Full Article
Stocks making the biggest moves midday: WBTN, STLD, HIMS - Finnoexpert
Check out the companies making the biggest moves midday: Webtoon Entertainment — Shares rallied 31% after the company reached a deal to create a digital comic platform for Disney. Webtoon also agreed to sell a 2% equity stake to the media giant. Emerson Electric — The engineering company fell 4.5%. Its management told a JPMorgan conference that fourth-quarter orders are likely to come in at the end of its guidance range, citing weakness in Europ…
Coverage Details
Total News Sources32
Leaning Left5Leaning Right2Center22Last UpdatedBias Distribution76% Center
Bias Distribution
- 76% of the sources are Center
76% Center
L 17%
C 76%
Factuality
To view factuality data please Upgrade to Premium
